

[illegible]

 **medanta**

Global Health Limited
CIN: L85110DL2004PLC128319

Regd. Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corp. Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana 122001, India
Tel: +91 124 483 4060 | E-mail: compliance@medanta.org | Website: <https://www.medanta.org>

| Sl. No. | Particulars | Quarter ended 31.12.2025 | Nine months period ended 31.12.2025 | Quarter ended 31.12.2024 |
|---------|---|--------------------------|-------------------------------------|--------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) |
| 1 | Revenue from operations | 11,210.47 | 32,511.06 | 9,434.36 |
| 2 | Net profit for the period (before tax and exceptional items) | 1,563.81 | 5,287.59 | 1,890.68 |
| 3 | Net profit for the period before tax (after exceptional items) | 1,197.83 | 5,277.38 | 1,890.68 |
| 4 | Net profit for the period after tax (after exceptional items) | 950.33 | 4,124.15 | 1,428.58 |
| 5 | Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)] | 956.53 | 4,123.45 | 1,457.41 |
| 6 | Paid up equity share capital | 537.58 | 537.58 | 537.17 |
| 7 | Reserves (excluding Revaluation Reserve)* | | | |
| 8 | Earnings Per Share (of Rs 2/- each) - | | | |
| | Basic: | 3.54 | 15.35 | 5.32 |
| | Diluted: | 3.54 | 15.32 | 5.32 |

* Reserves (excluding Revaluation Reserve) as on 31 March 2025 was Rs 33,326.93 Million.


| Sl. No. | Particulars | Quarter ended 31.12.2025 | Nine months period ended 31.12.2025 | Quarter ended 31.12.2024 |
|---------|---|--------------------------|-------------------------------------|--------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) |
| 1 | Revenue from operations | 9,401.65 | 27,487.49 | 8,123.67 |
| 2 | Net profit for the period (before tax and exceptional items) | 1,380.86 | 4,858.02 | 1,752.75 |
| 3 | Net profit for the period before tax (after exceptional items) | 1,028.86 | 4,861.79 | 1,752.75 |
| 4 | Net profit for the period after tax (after exceptional items) | 799.07 | 3,720.70 | 1,313.86 |
| 5 | Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax)) | 803.83 | 3,719.73 | 1,339.41 |

Notes:

1. These results have been reviewed and recommended by the Audit Committee and accordingly approved by the Board of Directors of the Company at their respective meetings held on 4 February 2026. The result have been subjected to the limited review by the statutory auditors of the Company.

2. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone Quarter/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also available at the company's website <https://www.medanta.org>.

Place: Gurugram
Date: 4 February 2026



By order of the Board
for **Global Health Limited**
Sd/-
Dr. Naresh Trehan
Chairman and Managing Director

IndusInd Bank

IndusInd Bank Limited

CIN: L65191PN1994PLC076333

Registered Office: 2401, Gen. Thimmayya Road (Cantonment), Pune - 411 001.

Secretarial & Investor Services: 701, Solitaire Corporate Park,
167, Guru Hargovindji Marg, Andheri (East), Mumbai - 400 093.

Tel No.: +91 6641 2487 / 6641 2359 • **Email ID:** investor@indusind.com • **Website:** www.indusind.bank.in

SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES OF INDUSIND BANK LIMITED


Pursuant to earlier, SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/PI/CIR/2025/97 dated July 2, 2025 and SEBI Circular No. SEBI/HO/38/13/11(2) 2026-MIRSD-POD/II/3750/2026 dated January 30, 2026, all Shareholders of the Bank are hereby informed that a Special Window is open for a period of one year, from February 05, 2026 to February 04, 2027, for re-lodgement of transfer requests of physical shares, which were lodged prior to the deadline of April 1, 2019 and which were rejected / returned / not attended to due to deficiency in the documents / process / or otherwise.


Investors that have missed earlier deadline of March 31, 2021 (the cut-off date for re-lodgement of transfer deeds) & January 06, 2026, are encouraged to take this opportunity by furnishing the necessary documents to the Bank's Registrar and Transfer Agent M/s MUFG Intime India Private Limited (formerly Link Intime India Private Limited), at C-101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400 083, Tel.: +91 810811 6767 / 1800 1020 878, e-mail: investor.helpdesk@in.mpmf.mufig.com.

For IndusInd Bank Ltd.
Sd/-
Anand Kumar Das
Company Secretary
Membership No. FCS-6950

Place: Mumbai
Date: February 04, 2026

| <p style="text-align: center;">E-Auction Sale Notice Under Insolvency and Bankruptcy Code, 2016 C. Mahendra Exports Limited - In Liquidation Regd office: Tower 'C', Office No. CC-6011, Bharat Diamond Bourse, Bandra Kurla Complex, Bandra (East), Mumbai - 400051 </p> | | | | |
|--|--|---------------------|--|------------------------------|
| E-Auction Sale of Assets of C. Mahendra Exports Limited (In Liquidation) will be conducted on "As is where is", "As is what is", "Whatever there is" and "No recourse" basis. DATE & TIME OF E-AUCTION: TUESDAY, FEBRUARY 24, 2026 FROM 11:30 AM TO 12:30 PM | | | | |
| Block | Asset | Reserve Price (Rs.) | Earnest Money Deposit (EMD) (Rs.) | Bid Incremental Amount (Rs.) |
| 1. | Office Premises at 612 and 612-A Prasad Chambers, Swadeshi Mills Compound, Opera House, Mumbai - 400004 | 3,95,55,000 | 39,55,500 | 4,00,000 |
| 2. | Land, Building, along with miscellaneous Plant and Machinery situated at Plot No. 26/9-A & A/26/10, Udhna Udyognagar Sahakar Sangh Limited, Udhna, Surat - 394210, Gujarat (Land Area 1296 Sq. Mtrs.; Building Area 24,183 sq.ft.) | 7,70,23,000 | 77,02,300 | 8,00,000 |
| 3. | Barren Land, Partly Jirayat & Sada-Pad Land situated at Survey No.474 & 476 Village Tisangli Taluka: Kavathe - Mahankar, Dist. Sangli - 416405, Maharashtra. (Survey No. 474 - 5,900 sq. mtrs. & Survey No. 476 - 2200 sq. mtrs) | 16,41,000 | 164,100 | 1,00,000 |
| 4. | Leased Land at Revenue Survey no.286/p, Village Shindodi Moti, Taluka - Abdasa, District: Kutch-Bhuj, Gujarat - 370645 admeasuring 10,000 sq. mtrs | 1,78,200 | 17,820 | 10,000 |
| 5. | Equity Shares of C. Mahendra International Limited (112,800 Equity Shares of 10 each fully paid up) | 10,33,64,100 | 1,03,36,410 | 10,00,000 |
| Terms and Conditions of the E-Auction are as under: | | | | |
| 1. The E-Auction sale shall be done through Bsnknet, via the website https://bbi.banknet.com (" Auction Portal "). | | | | |
| 2. The intending bidders are required to submit their Earnest Money Deposit (" EMD ") through the auction portal latest by 23 February 2026, 6:00 PM. | | | | |
| 3. Prospective bidders shall submit the requisite documents, including a declaration of eligibility under Section 29A of the Insolvency and Bankruptcy Code through the auction portal only. EMD of the highest bidder shall be forfeited if found ineligible anytime during the process. | | | | |
| 4. All the terms, conditions, information related to assets and auction is provided in the Process Memorandum and is available on the auction portal. The requirement for information / data room has to be sent through Email id: cirpcel@gmail.com . | | | | |
| 5. Interest bidders shall register, upload their eligibility documents, bid and receive confirmation of their bid by electronic means through auction portal only. | | | | |
| 6. The Liquidator reserves the right to accept or reject or cancel any bid or modify any terms and conditions of process memorandum / E-Auction at any time without assigning any reason. The Liquidator also reserves the right to cancel the E-Auction at any time without assigning any reason. | | | | |
| Date: February 5, 2026 Place: Mumbai | | | Sd/ Krishna Chaudhari Liquidator - C. Mahendra Exports Limited IBBI Registration Number: IBBI/IPA-001/IP-P00694/2017-18/11220 | |

| <div>  </div> | | | | | | | | | | | | | |
|---|--|---------------|-------------|-------------|-------------------|-------------|-------------|---------------|-------------|-------------|-------------------|-------------|-------------|
| EUREKA FORBES LIMITED | | | | | | | | | | | | | |
| CIN : L27310MH2008PLC188478 | | | | | | | | | | | | | |
| Registered Office: B1/B2, 7 th Floor, 701, Marathon Innova, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra - 400013, India. Phone No.: +91 22 4882 1700 Fax No.: +91 22 4882 1701 Website: www.eurekaforbes.com E-mail: compliance@eurekaforbes.com | | | | | | | | | | | | | |
| EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 | | | | | | | | | | | | | |
| (Rs. in Lakhs) | | | | | | | | | | | | | |
| Sr. No. | Particulars | STANDALONE | | | | | | CONSOLIDATED | | | | | |
| | | Quarter ended | | | Nine Months ended | | Year ended | Quarter ended | | | Nine Months ended | | Year ended |
| | | 31.12.2025 | 30.09.2025 | 31.12.2024 | 31.12.2025 | 31.12.2024 | 31.03.2025 | 31.12.2025 | 30.09.2025 | 31.12.2024 | 31.12.2025 | 31.12.2024 | 31.03.2025 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Total income from operations | 65,056.48 | 77,931.80 | 60,223.49 | 2,04,476.40 | 1,83,331.62 | 2,45,016.44 | 65,081.54 | 77,805.59 | 60,217.99 | 2,04,418.15 | 1,83,443.23 | 2,45,147.89 |
| 2 | Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*) | 5,280.31 | 8,316.35 | 4,694.68 | 18,765.92 | 14,791.73 | 21,379.25 | 5,413.20 | 8,496.88 | 4,731.37 | 19,117.23 | 15,123.34 | 21,652.09 |
| 3 | Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items*) | 1,236.13 | 8,316.35 | 4,694.68 | 14,721.74 | 15,091.73 | 21,886.94 | 1,369.02 | 8,496.88 | 4,731.37 | 15,073.05 | 15,423.34 | 22,069.78 |
| 4 | Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items*) | 900.22 | 6,158.86 | 3,482.22 | 10,911.30 | 11,253.47 | 16,328.65 | 997.88 | 6,291.75 | 3,503.36 | 11,159.54 | 11,493.37 | 16,441.47 |
| 5 | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 1,197.29 | 6,073.03 | 3,423.36 | 11,036.68 | 11,076.93 | 15,985.24 | 1,283.93 | 6,248.12 | 3,420.28 | 11,314.26 | 11,298.21 | 16,096.51 |
| 6 | Equity Share Capital | 19,349.18 | 19,349.18 | 19,347.92 | 19,349.18 | 19,347.92 | 19,347.92 | 19,349.18 | 19,349.18 | 19,347.92 | 19,349.18 | 19,347.92 | 19,347.92 |
| 7 | Reserves (excluding Revaluation Reserve as shown in the Balance Sheet) | | | | | | 4,19,149.15 | | | | | | 4,21,520.82 |
| 8 | Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) - | | | | | | | | | | | | |
| | 1. Basic: | 0.46 | 3.17 | 1.80 | 5.61 | 5.82 | 8.40 | 0.52 | 3.23 | 1.81 | 5.74 | 5.94 | 8.46 |
| | 2. Diluted:* | 0.46* | 3.17* | 1.79* | 5.61* | 5.80* | 8.40* | 0.52* | 3.23* | 1.81* | 5.74* | 5.92* | 8.46* |
| * Impact due to grant of Stock Options has been considered while arriving at the diluted EPS. | | | | | | | | | | | | | |
| # Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable. | | | | | | | | | | | | | |
| Notes: | | | | | | | | | | | | | |
| 1. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 04, 2026. | | | | | | | | | | | | | |
| 2. The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and Company's website at www.eurekaforbes.com. The same can be accessed on the Company's website by scanning the QR Code provided below: | | | | | | | | | | | | | |
| <div> </div> | | | | | | | | | | | | | |

| <div>  <h1>Aarti Drugs Limited</h1> </div> | | | | | | | | | | | | |
|---|---------------|------------|------------|--------------|------------|------------|---------------|------------|------------|--------------|------------|------------|
| <div> <p>Registered Office: Plot No. N-198, MIDC, Tarapur, Village Pamtermbhi, Dist. Palghar - 401 506, Maharashtra</p> <p>CIN: L37060MH1984PLC055433 Email ID: investorrelations@aartidrugs.com Website: www.aartidrugs.com</p> </div> | | | | | | | | | | | | |
| STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025 | | | | | | | | | | | | |
| (₹ In Lacs except for share data) | | | | | | | | | | | | |
| PARTICULARS | Standalone | | | | | | Consolidated | | | | | |
| | Quarter Ended | | | Period Ended | | Year Ended | Quarter Ended | | | Period Ended | | Year Ended |
| | 31.12.2025 | 30.09.2025 | 31.12.2024 | 31.12.2025 | 31.12.2024 | 31.03.2025 | 31.12.2025 | 30.09.2025 | 31.12.2024 | 31.12.2025 | 31.12.2024 | 31.03.2025 |
| | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) |
| Total income | 53,002 | 57,910 | 52,591 | 163,047 | 156,256 | 218,723 | 60,294 | 65,288 | 56,850 | 184,664 | 172,476 | 240,339 |
| Net profit for the period | | | | | | | | | | | | |
| (before tax, exceptional and/or extraordinary items) | 2,171 | 5,578 | 5,203 | 12,274 | 12,808 | 19,875 | 2,902 | 6,041 | 5,076 | 14,054 | 14,062 | 21,177 |
| Exceptional items | - | - | - | - | - | - | - | - | - | - | - | - |
| Net profit for the period after Tax | | | | | | | | | | | | |
| (after exceptional and/or extraordinary items) | 3,384 | 4,178 | 3,853 | 12,426 | 9,583 | 15,731 | 4,055 | 4,516 | 3,709 | 13,968 | 10,533 | 16,810 |
| Other Comprehensive Income (after tax) | - | - | - | - | - | 113 | 31 | - | (46) | 43 | 31 | 159 |
| Total Comprehensive Income for the period | 3,384 | 4,178 | 3,853 | 12,426 | 9,583 | 15,844 | 4,086 | 4,516 | 3,663 | 14,011 | 10,563 | 16,969 |
| Weighted average number of equity shares used for computing earning per share (face value of Rs. 10 each) | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 | 9,127 |
| Earning per share (in Rs.) (not annualised) | | | | | | | | | | | | |
| (a) Basic | 3.71 | 4.58 | 4.22 | 13.61 | 10.50 | 17.18 | 4.44 | 4.95 | 4.06 | 15.30 | 11.54 | 18.35 |
| (b) Diluted | 3.71 | 4.58 | 4.22 | 13.61 | 10.50 | 17.18 | 4.44 | 4.95 | 4.06 | 15.30 | 11.54 | 18.35 |


Notes:

- The above results for the Quarter & Period ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd February, 2026.
- The Board of Directors have declared interim Dividend of Rs.2.00/- (Rupee Two) per Equity Share of Rs. 10/- each (20%) amounting to Rs.18,25,40,000 for the Period ended 31st December,2025.
- As on December 31, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA.
- The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors' fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)("Buyback Size") on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each.
- On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment has also published draft Central Rules and FAQs on aforesaid labour codes. The detailed impact assessment is currently in progress, necessary adjustments, if any, will be identified and appropriately accounted for in Q4 FY 2025-26.
- Company has only one business segment i.e. pharmaceuticals.
- The Company's new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results are uploaded on the Company's website www.aartidrugs.com and also available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. The Same data can be accessed by scanning the QR code provided below:

For Aarti Drugs Limited
 Sd/-
 Prakash M. Patil
 Chairman, Managing Director & CEO
 DIN: 00005618

Place: Mumbai
 Date: 3rd February, 2026

www.paperfinancialexpress.com



WESTLIFE FOODWORLD LIMITED

Regd. Office : 1001, Tower - 3, 10th Floor, One International Center,
Senapati Bapat Marg, Prabhadevi, Mumbai 400 013.

CIN No. : L65990MH1982PLC028593 Tel : 022-4913 5000 Fax : 022-4913 5001

Website : www.westlife.co.in | E-mail id : shataadn@mcDonaldsindia.com

**Extract of Unaudited Consolidated Financial Results for the quarter and
nine months ended December 31, 2025**

(Rs. in Lakhs)

| Particulars | 3 months ended 31/12/2025 | Preceding 3 months ended 30/09/2025 | Correspond- ing 3 months ended 31/12/2024 | Year to date figures for the period ended 31/12/2025 | Year to date figures for the period ended 31/12/2024 | Year ended 31/03/2025 |
|--|---------------------------------|--|--|--|--|-----------------------------|
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Total Income | 67,813.25 | 65,255.03 | 65,665.58 | 199,512.33 | 190,257.01 | 257,566.68 |
| Profit before tax for the period / year | 201.24 | 3,695.32 | 648.73 | 4,062.58 | 1,170.88 | 1,304.55 |
| Profit after tax for the period / year | 102.01 | 2,770.94 | 701.18 | 2,995.70 | 1,062.42 | 1,214.68 |
| Total Comprehensive income for the period / year | 56.83 | 2,773.95 | 665.70 | 2,938.56 | 955.76 | 1,154.98 |
| Earnings Per Share (not annualised) - (Face value of Rs 2 each) | | | | | | |
| Basic (in Rs.) | 0.07 | 1.78 | 0.45 | 1.92 | 0.68 | 0.77 |
| Diluted (in Rs.) | 0.07 | 1.78 | 0.45 | 1.92 | 0.68 | 0.77 |

Note:


1) The above is an extract of the detailed format of Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the stock exchange websites: www.bseindia.com and www.nseindia.com and Company's website : www.westlife.co.in. The same can be accessed by scanning the QR code provided below.

2) The Standalone financial results are available on the Company's website "www.westlife.co.in" and on the website of the stock exchange www.bseindia.com and www.nseindia.com. Key numbers of Standalone results of the Company are as under :

| Particulars | 3 months ended 31/12/2025 | Preceding 3 months ended 30/09/2025 | Correspond- ing 3 months ended 31/12/2024 | Year to date figures for the period ended 31/12/2025 | Year to date figures for the period ended 31/12/2024 | Year ended 31/03/2025 |
|---|---------------------------------|--|--|--|--|-----------------------------|
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Total Income | 27.23 | 29.88 | 26.62 | 1,553.63 | 85.36 | 123.99 |
| Profit/(Loss) before tax for the period / year | (0.84) | (13.25) | (14.27) | 1,438.23 | (42.46) | (37.66) |
| Profit/(Loss) after tax for the period / year | (0.84) | (13.25) | (14.27) | 1,438.23 | (42.46) | 88.99 |
| Total comprehensive income / (loss) for the period / year | (0.84) | (13.25) | (14.27) | 1,438.23 | (42.46) | 88.99 |

3) The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 04, 2026.

Mumbai
February 04, 2026



For and on behalf of the Board
(sd/-)
Amrit Jatin
Chairman
DIN: 0001687